about
Enhanced self-administration of the CB1 receptor agonist WIN55,212-2 in olfactory bulbectomized rats: evaluation of possible serotonergic and dopaminergic underlying mechanisms.Late-stage α-synuclein accumulation in TNWT-61 mouse model of Parkinson's disease detected by diffusion kurtosis imaging.Sex Differences in the Reinstatement of Methamphetamine Seeking after Forced Abstinence in Sprague-Dawley Rats.Health safety issues of synthetic food colorants.Aripiprazole-induced adverse metabolic alterations in polyI:C neurodevelopmental model of schizophrenia in rats.Reactivity to addictive drugs in the methylazoxymethanol (MAM) model of schizophrenia in male and female rats.Depot risperidone-induced adverse metabolic alterations in female rats.Olanzapine-depot administration induces time-dependent changes in adipose tissue endocrine function in rats.[Effectiveness of phytotherapy in supportive treatment of type 2 diabetes mellitus III. Momordica (Momordica charantia)].Suppression of Methamphetamine Self-Administration by Ketamine Pre-treatment Is Absent in the Methylazoxymethanol (MAM) Rat Model of Schizophrenia.Anticancer Activity of Artemisinin and its Derivatives.Differential characteristics of ketamine self-administration in the olfactory bulbectomy model of depression in male rats.Low Vs. High Alcohol: Central Benefits Vs. Detriments.Principles of Diffusion Kurtosis Imaging and its Role in Early Diagnosis of Neurodegenerative Disorders.HDAC1 and HDAC3 underlie dynamic H3K9 acetylation during embryonic neurogenesis and in schizophrenia-like animals.Poly(I:C) model of schizophrenia in rats induces sex-dependent functional brain changes detected by MRI that are not reversed by aripiprazole treatment.Reward related neurotransmitter changes in a model of depression: An in vivo microdialysis study.Olfactory bulbectomy increases reinstatement of methamphetamine seeking after a forced abstinence in rats.Diffusion Kurtosis Imaging Detects Microstructural Alterations in Brain of α-Synuclein Overexpressing Transgenic Mouse Model of Parkinson's Disease: A Pilot Study.Early and progressive microstructural brain changes in mice overexpressing human α-Synuclein detected by diffusion kurtosis imaging.The effects of methamphetamine self-administration on behavioural sensitization in the olfactory bulbectomy rat model of depression.Both ketamine and NBQX attenuate alcohol drinking in male Wistar rats.[Milk Thistle (Silybum Marianum) as a Supportive Phytotherapeutic Agent in Oncology].[Active substances from marine organisms in clinical trials and practice].Prenatal exposure to modafinil alters behavioural response to methamphetamine in adult male mice.Sex and Feeding Status Differently Affect Natural Reward Seeking Behavior in Olfactory Bulbectomized RatsDifferent effects of prenatal MAM vs. perinatal THC exposure on regional cerebral blood perfusion detected by Arterial Spin Labelling MRI in rats[Curcumine (Turmeric - Curcuma longa) as a Supportive Phytotherapeutic Treatment in Oncology]Improved Pharmacokinetics and Tissue Uptake of Complexed Daidzein in RatsPrenatal exposure to modafinil alters locomotor behaviour and leucocyte phagocytosis in miceDiffusion Kurtosis Imaging Detects Microstructural Changes in a Methamphetamine-Induced Mouse Model of Parkinson's DiseasePeripubertal cannabidiol treatment rescues behavioral and neurochemical abnormalities in the MAM model of schizophrenia
P50
Q30574411-14050A95-2DC1-4582-B89C-443026AC5A94Q31032932-D57E2AA5-AB7B-4C15-9709-F0A738ABEEEEQ35819948-08D8F059-E25F-4675-BCC7-4F6E52542FEDQ38592497-F9149F62-290E-4116-B68E-1CF1144E7C79Q38735631-42FB2A8D-57AF-4920-BBFE-CE63380D0CDDQ38862631-832B39CE-9F0D-4A6E-8534-CF2853F8CA05Q38873420-D9FC77E8-70F5-421D-9CA9-FF8D9A6C5226Q39508296-F7106EE7-05C7-4E62-858F-2C139551DBEBQ40956407-9816BBDE-E7E3-49F1-8005-27A760B31540Q42034477-82B2A945-5590-4920-B71E-82A2B9DCBE90Q46276900-D9FCCCE2-35A0-4BAE-8B43-8E545A23563BQ47318834-8BC4DCE8-BB07-40EF-A3F8-EC52B00A3D63Q47663680-9FAC6C57-D970-4E78-8B12-A6CBAE9F1D65Q47697222-AFFCE15C-B201-4EA5-B612-6D70D5CCC5B5Q47953829-95B78A52-B9C3-4D06-8AC9-0B6F00539627Q47961935-C1677897-9C6C-4039-8133-FDB90593075BQ48073091-62117AE8-3384-4561-90F2-2FFF45306A9FQ48073379-A576EA46-EE00-4829-8C06-737B2BC25726Q48090438-5AAACB55-3A2E-47D0-9DCD-89C786A5448EQ48404173-8FBFC0A9-28A8-412C-A5DF-38F708CB166AQ48800496-DAC8100E-32BC-4388-A39B-5A7D63E7D245Q49392046-42C02257-01DB-4807-AB76-58C4F6ED2F25Q52405784-6D332AC1-BD60-4A6B-98CD-B615A2F46BEAQ52603192-64808E80-45E0-4030-B28A-0E590827D18EQ53835422-FFB97159-8BC8-4589-8C96-6301EA099AFDQ58693847-98140012-89AE-4A0D-9CD0-0EB7DB69ACEBQ64115479-FAD16A97-F577-4489-9234-91E7AE045A80Q87906256-53454878-620F-441C-84F4-27F287BA2A1FQ89804795-7466B94F-9D05-41E7-96C7-4F9DB278C3CCQ91865603-7C5A4BD4-5ED5-420B-A0F0-9F602F2211E2Q92830098-AF00C49F-46CC-4F50-A2D0-32E8942E6142Q93368884-98BDE16E-772F-445D-8854-5FC1BC920BD2
P50
description
farmakoložka, farmaceutka
@cs
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Jana Ruda-Kucerova
@nl
Jana Rudá-Kučerová
@cs
Jana Rudá-Kučerová
@en
Jana Rudá-Kučerová
@es
type
label
Jana Ruda-Kucerova
@nl
Jana Rudá-Kučerová
@cs
Jana Rudá-Kučerová
@en
Jana Rudá-Kučerová
@es
altLabel
Jana Ruda-Kucerova
@en
prefLabel
Jana Ruda-Kucerova
@nl
Jana Rudá-Kučerová
@cs
Jana Rudá-Kučerová
@en
Jana Rudá-Kučerová
@es
P106
P214
P1153
56682717600
56716550300
P19
P21
P214
P31
P496
0000-0002-1846-0799
P569
1980-01-20T00:00:00Z
P691
P735
P7859
viaf-85745665